LTRN insider trading
NasdaqCM HealthcareLantern Pharma Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Lantern Pharma Inc.
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Company website: www.lanternpharma.com
LTRN insider activity at a glance
FilingIQ has scored 168 insider transactions for LTRN since Jun 11, 2020. The most recent filing in our index is dated May 12, 2026.
Across the full history, 5 open-market purchases
and 124 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on LTRN insider trades is 52.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Top insiders trading LTRN
Frequently asked
- How many insider trades does FilingIQ track for LTRN?
- FilingIQ tracks 168 Form 4 insider transactions for LTRN (Lantern Pharma Inc.), covering filings from Jun 11, 2020 onwards. 4 of those were filed in the last 90 days.
- Are LTRN insiders net buyers or net sellers?
- Across the full Form 4 history for LTRN, 5 transactions (3%) were open-market purchases and 124 (74%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does LTRN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is LTRN in?
- Lantern Pharma Inc. (LTRN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $23.93M.
Methodology & sources
Every LTRN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.